Literature DB >> 33035831

A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease.

Jun-Ju Zou1, Xiao-Tao Zhou1, Yan-Kun Chen2, Jia-Lu Liu3, Cheng Wang4, Yue-Rong Ma5, Li Wang6.   

Abstract

Chronic kidney disease (CKD) is one of the most common conditions which significantly increases the risk for serious health outcomes. Epidemiological investigations have shown that CKD has become a serious global health problem. At present, there are no treatments for CKD, thus the need for an effective and safe treatment for this condition. Shenkang Injection (SKI), which is an herbal medication in Chinese Medicine, has been used in the management and treatment of CKD and has achieved favorable therapeutic effects. The purpose of this paper is to review the clinical efficacy, mechanism of action, and safety profile of SKI when used in CKD, and to provide comprehensive potential evidence for its clinical application.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Renal fibrosis; Shenkang injection; Traditional Chinese medicine

Mesh:

Substances:

Year:  2020        PMID: 33035831     DOI: 10.1016/j.biopha.2020.110833

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.

Authors:  Junju Zou; Xiaotao Zhou; Xian Chen; Yuerong Ma; Rong Yu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway.

Authors:  Hui-Ting Wei; Yuan Xu; Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

3.  Efficacy and safety of Shenkang injection as adjuvant therapy in patients with diabetic nephropathy: A protocol for systematic review and meta-analysis.

Authors:  Yanping Wang; Mingzhu Li; Chenyun Li; Sheng Xu; Jiangfeng Wu; Gaochuan Zhang; Yuanyuan Cai
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.889

Review 4.  A Review of Traditional Chinese Medicine in Treating Renal Interstitial Fibrosis via Endoplasmic Reticulum Stress-Mediated Apoptosis.

Authors:  Yu Liu; Dan-Qian Chen; Jing-Xue Han; Ting-Ting Zhao; Shu-Ju Li
Journal:  Biomed Res Int       Date:  2021-05-15       Impact factor: 3.246

5.  Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways.

Authors:  Liang-Pu Luo; Ping Suo; Li-Li Ren; Hong-Jiao Liu; Yamei Zhang; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

Review 6.  Research Progress on the Positive and Negative Regulatory Effects of Rhein on the Kidney: A Review of Its Molecular Targets.

Authors:  Yanna Zhu; Shilei Yang; Linlin Lv; Xiaohan Zhai; Guoyu Wu; Xiaolin Qi; Deshi Dong; Xufeng Tao
Journal:  Molecules       Date:  2022-10-04       Impact factor: 4.927

7.  Research and application of herbal medicine in the treatment of chronic kidney disease since the 21st century: A visualized bibliometric analysis.

Authors:  Yunling Xu; Jia Chen; He Wang; Ying Lu
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

8.  Effects of Shenkang Injection Combined with Jinshuibao on Early Diabetic Nephropathy and Effects on Coagulation Fibrinolysis System and Urinary Protein.

Authors:  Jianhua Zhu; Tingting Yang; Jie Luo; Mian Wei; Hanyu Li; Yue Qi; Jiali He; Min Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-11       Impact factor: 2.650

9.  Protective impact of Spirulina platensis against γ-irradiation and thioacetamide-induced nephrotoxicity in rats mediated by regulation of micro-RNA 1 and micro-RNA 146a.

Authors:  Asmaa A Salem; Amel F M Ismail
Journal:  Toxicol Res (Camb)       Date:  2021-04-28       Impact factor: 3.524

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.